 |
CORSO: Breast Cancer controversies
This house believes that...
Chieti, 27 June 2016 |
Direttore: Ettore Cianchetti, Clara Natoli |
| CREDITI ECM: 6 |
SCARICA IL PDF... |
|
|
|
|
|
|
|
|
| PROGRAMMA DEL CORSO (CLICCARE SULLE ICONE PER SCARICARE LE SLIDES) |
|
La partecipazione è gratuita.
Le iscrizioni si accettano esclusivamente on line sul sito
del Provider www.strategieonweb.it - pagina ECM 2016 |
|
|
| 10:15 |
Introduction and Authorities welcome |
|
|
|
|
| I session |
| Moderatori: Corrado Ficorella, L’Aquila & Clara Natoli, Chieti |
|
| 10:30 |
THBT Italian breast cancer screening guidelines should be updated |
Marzia Muzi, Ortona |
|
|
| 10:45 |
Discussion leader: Doralba Morrone, Firenze |
|
|
|
| 11:00 |
THBT neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm |
Valentina Guarneri, Padova |
|
|
| 11:15 |
Discussion leader: Antonio Frassoldati, Ferrara |
|
|
|
| 11:30 |
THBT selected HER2/++ FISH negative breast cancer should be considered as HER2/+++ |
Domenico Angelucci, Ortona |
|
|
| 11:45 |
Discussion leader: Patrizia Querzoli, Ferrara |
|
|
|
| 12:00 |
THBT axillary lymph node dissection should be avoided in patients with 1–2 macro-metastatic axillary nodes |
Ettore Cianchetti, Ortona |
|
|
| 12:15 |
Discussion leader: Mario Taffurelli, Bologna |
|
|
|
| 12:30 |
THBT hypo-fractionated irradiation and partial breast irradiation are recommended after breast conserving surgery |
Domenico Genovesi, Chieti |
|
|
| 12:45 |
Discussion leader: Lorenzo Livi, Firenze |
|
|
|
| 13:00 |
THBT chemoprevention and prophylactic surgery should be offered to healthy women carrying BRCA1/2 mutations |
Laura Cortesi, Modena |
|
|
| 13:15 |
Discussion leader: Francesco Fanfani, Chieti |
|
|
|
|
|
|
| II session |
| Moderatori: Amedeo Pancotti, Teramo & Carlo Garufi , Pescara |
|
| 14:30 |
THBT that fertility should be preserved in young women with early breast cancer |
Gianmario Tiboni, Ortona |
|
|
| 14:45 |
Discussion leader: Lucio Laudadio, Lanciano |
|
|
|
| 15:00 |
THBT metronomic chemotherapy has an emerging role for breast cancer treatment |
Elisabetta Munzone, Milano |
|
|
| 15:15 |
Discussion leader: Vito Lorusso, Bari |
|
|
|
| 15:30 |
THBT that neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer women |
Antonino Grassadonia, Chieti |
|
|
| 15:45 |
Discussion leader: Silvana Leo, Lecce |
|
|
|
|
|
| 16:15 |
THBT endocrine combination therapies are recommended for RE+ HER2- tumors |
Katia Cannita, L'Aquila |
|
|
| 16:30 |
Discussion leader: Serena Di Cosimo, Milano |
|
|
|
|
| III session |
| Moderatori: Antonio Nuzzo, Lanciano & Clara Natoli, Chieti |
|
| 16:45 |
THBT taxanes and bevacizumab are the standard fi rst line therapy for HER2- metastatic breast cancer |
Luca Moscetti, Modena |
|
|
| 17:00 |
Discussion leader: Giorgio Mustacchi, Trieste |
|
|
|
| 17:15 |
THBT metastatic triple positive breast cancer needs different therapeutic strategies than HER2-enriched tumors |
Patrizia Vici, Rome |
|
|
| 17:30 |
Discussion leader: Andrea Michelotti, Pisa |
|
|
|
| 17:45 |
Conclusions |
Clara Natoli & Ettore Cianchetti |
|
|
| 18:00 |
Questionario di valutazione dell'apprendimento |
|
|
|
| 18:15 |
Chiusura dei lavori |
|
|
|